JP2018511628A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511628A5
JP2018511628A5 JP2017553879A JP2017553879A JP2018511628A5 JP 2018511628 A5 JP2018511628 A5 JP 2018511628A5 JP 2017553879 A JP2017553879 A JP 2017553879A JP 2017553879 A JP2017553879 A JP 2017553879A JP 2018511628 A5 JP2018511628 A5 JP 2018511628A5
Authority
JP
Japan
Prior art keywords
seq
group
alkyl
formula
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017553879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511628A (ja
Filing date
Publication date
Priority claimed from GBGB1506393.6A external-priority patent/GB201506393D0/en
Application filed filed Critical
Publication of JP2018511628A publication Critical patent/JP2018511628A/ja
Publication of JP2018511628A5 publication Critical patent/JP2018511628A5/ja
Pending legal-status Critical Current

Links

JP2017553879A 2015-04-15 2016-04-15 部位特異的な抗体−薬物複合体 Pending JP2018511628A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506393.6A GB201506393D0 (en) 2015-04-15 2015-04-15 Site-specific antibody-drug conjugates
GB1506393.6 2015-04-15
PCT/EP2016/058371 WO2016166299A1 (en) 2015-04-15 2016-04-15 Site-specific antibody-drug conjugates

Publications (2)

Publication Number Publication Date
JP2018511628A JP2018511628A (ja) 2018-04-26
JP2018511628A5 true JP2018511628A5 (https=) 2019-05-09

Family

ID=53333825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017553879A Pending JP2018511628A (ja) 2015-04-15 2016-04-15 部位特異的な抗体−薬物複合体

Country Status (11)

Country Link
US (1) US20180125994A1 (https=)
EP (1) EP3283118A1 (https=)
JP (1) JP2018511628A (https=)
KR (1) KR20170137115A (https=)
CN (1) CN107683146A (https=)
AU (1) AU2016249877A1 (https=)
BR (1) BR112017022256A2 (https=)
CA (1) CA2981920A1 (https=)
GB (1) GB201506393D0 (https=)
MX (1) MX2017013154A (https=)
WO (1) WO2016166299A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX375569B (es) 2017-02-08 2025-03-04 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepinas y anticuerpos
SI3579883T1 (sl) 2017-02-08 2021-12-31 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PT3612537T (pt) 2017-04-18 2022-08-29 Medimmune Ltd Conjugados de pirrolobenzodiazepina
AU2018253950A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-CD25 antibody-drug conjugate
WO2018193103A1 (en) * 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-psma antibody-drug conjugate
BR112019026498A2 (pt) 2017-06-14 2020-07-14 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd25
DK3668874T3 (da) 2017-08-18 2022-02-14 Medimmune Ltd Pyrrolobenzodiazepin-konjugater
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201820725D0 (en) 2018-12-19 2019-01-30 Adc Therapeutics Sarl Pyrrolobenzodiazepine resistance
US20220347309A1 (en) 2018-12-19 2022-11-03 Adc Therapeutics Sa Pyrrolobenzodiazepine resistance
KR102890251B1 (ko) 2019-03-15 2025-11-25 메드임뮨 리미티드 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트
HUE060364T2 (hu) * 2019-03-29 2023-02-28 Medimmune Ltd Vegyületek és konjugátumaik
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
TW202140076A (zh) * 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
MX2024002476A (es) * 2021-08-27 2024-05-20 Janssen Biotech Inc Anticuerpos anti-psma y usos de estos.
CN116370651A (zh) * 2023-04-04 2023-07-04 上海愿智生物技术有限公司 一种抗psma抗体-药物缀合物及其制备方法和应用
TW202542201A (zh) * 2023-12-29 2025-11-01 瑞士商T O A D 腫瘤學股份有限公司 抗psma軛合物及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20003099A3 (cs) * 1998-02-25 2002-04-17 Lexigen Pharmaceuticals Corporation Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek
EP1817341A2 (en) * 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
JP5889181B2 (ja) * 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
WO2012064733A2 (en) * 2010-11-09 2012-05-18 Medimmune, Llc Antibody scaffold for homogenous conjugation
US10751346B2 (en) * 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
EP2906250B1 (en) * 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
PE20160209A1 (es) * 2013-08-28 2016-05-09 Stemcentrx Inc Conjugados anti-dll3 (ligando3 tipo delta) manipulados y metodos de uso

Similar Documents

Publication Publication Date Title
JP2018511628A5 (https=)
JP2018516243A5 (https=)
JP2018502902A5 (https=)
JP2020506951A5 (https=)
JP2020531471A5 (https=)
JP2016508130A5 (https=)
IL315310A (en) Irak degraders and uses thereof
RU2019122802A (ru) Конъюганты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы
JP2018516860A5 (https=)
RU2019138337A (ru) Конъюгаты на основе антитела, содержащие агонист toll-подобного рецептора, и виды комбинированной терапии
JP2019502650A5 (ja) 抗ErbB2抗体−薬物コンジュゲート及びその組成物、そのための調製方法、並びにその使用
JP2020514419A5 (https=)
JP2014527974A5 (https=)
JP2021524449A5 (https=)
JP2016505586A5 (https=)
JP2014528466A5 (https=)
JP2014528467A5 (https=)
JP2017518040A5 (https=)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
JP2018070648A5 (https=)
JP2013505946A5 (https=)
JP2016531915A5 (https=)
JP2017506234A5 (https=)
JP2020519643A5 (https=)
JP2017528467A5 (https=)